Published in Biochem J on November 15, 2002
SAK, a new polo-like kinase, is transcriptionally repressed by p53 and induces apoptosis upon RNAi silencing. Neoplasia (2005) 1.08
CREB binding protein (CBP) activation is required for luteinizing hormone beta expression and normal fertility in mice. Mol Cell Biol (2012) 0.78
T₃-induced liver AMP-activated protein kinase signaling: redox dependency and upregulation of downstream targets. World J Gastroenterol (2014) 0.75
p53, the cellular gatekeeper for growth and division. Cell (1997) 31.04
The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell (1996) 16.57
Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor. Nature (1995) 11.53
Association between an oncogene and an anti-oncogene: the adenovirus E1A proteins bind to the retinoblastoma gene product. Nature (1988) 10.98
The CBP co-activator is a histone acetyltransferase. Nature (1997) 10.91
Nuclear protein CBP is a coactivator for the transcription factor CREB. Nature (1994) 9.37
Molecular cloning and functional analysis of the adenovirus E1A-associated 300-kD protein (p300) reveals a protein with properties of a transcriptional adaptor. Genes Dev (1994) 8.92
Retinoblastoma protein recruits histone deacetylase to repress transcription. Nature (1998) 8.75
Rb interacts with histone deacetylase to repress transcription. Cell (1998) 7.22
Oncogenic forms of p53 inhibit p53-regulated gene expression. Science (1992) 6.73
Binding and modulation of p53 by p300/CBP coactivators. Nature (1997) 5.12
Recruitment of p300/CBP in p53-dependent signal pathways. Cell (1997) 5.10
An adenovirus E1a protein region required for transformation and transcriptional repression. Cell (1986) 4.56
SUMO-1 modification activates the transcriptional response of p53. EMBO J (1999) 4.19
Thyroid hormone receptors: multiple forms, multiple possibilities. Endocr Rev (1993) 3.70
The nuclear hormone receptor coactivator SRC-1 is a specific target of p300. Proc Natl Acad Sci U S A (1996) 3.43
Interaction of thyroid-hormone receptor with a conserved transcriptional mediator. Nature (1995) 3.27
Mammalian Srb/Mediator complex is targeted by adenovirus E1A protein. Nature (1999) 3.24
Activation of p53 by conjugation to the ubiquitin-like protein SUMO-1. EMBO J (1999) 3.08
Mapping of cellular protein-binding sites on the products of early-region 1A of human adenovirus type 5. Mol Cell Biol (1988) 3.07
Serine15 phosphorylation stimulates p53 transactivation but does not directly influence interaction with HDM2. EMBO J (1999) 3.00
Identification of specific adenovirus E1A N-terminal residues critical to the binding of cellular proteins and to the control of cell growth. J Virol (1993) 2.92
Differential ligand-dependent interactions between the AF-2 activating domain of nuclear receptors and the putative transcriptional intermediary factors mSUG1 and TIF1. EMBO J (1996) 2.47
Promoter targeting by adenovirus E1a through interaction with different cellular DNA-binding domains. Nature (1994) 2.42
A novel thyroid hormone receptor encoded by a cDNA clone from a human testis library. Science (1987) 2.21
A novel function of the transforming domain of E1a: repression of AP-1 activity. Cell (1990) 1.97
The zinc finger region of the adenovirus E1A transactivating domain complexes with the TATA box binding protein. Proc Natl Acad Sci U S A (1994) 1.82
Advances in our understanding of thyroid hormone action at the cellular level. Endocr Rev (1987) 1.57
Negative regulation of the thyroid-stimulating hormone alpha gene by thyroid hormone: receptor interaction adjacent to the TATA box. Proc Natl Acad Sci U S A (1989) 1.54
Nuclear receptor corepressors activate rather than suppress basal transcription of genes that are negatively regulated by thyroid hormone. Mol Cell Biol (1997) 1.52
Identification of the gal4 suppressor Sug1 as a subunit of the yeast 26S proteasome. Nature (1996) 1.47
Functional characterization of the rat growth hormone promoter elements required for induction by thyroid hormone with and without a co-transfected beta type thyroid hormone receptor. J Biol Chem (1989) 1.39
Inhibition of p53-mediated transactivation and cell cycle arrest by E1A through its p300/CBP-interacting region. Oncogene (1997) 1.36
Characterization of a thyroid hormone receptor expressed in human kidney and other tissues. Proc Natl Acad Sci U S A (1988) 1.33
A thyroid hormone receptor coactivator negatively regulated by the retinoblastoma protein. Proc Natl Acad Sci U S A (1997) 1.31
Ligand-induced recruitment of a histone deacetylase in the negative-feedback regulation of the thyrotropin beta gene. EMBO J (1999) 1.25
Pituitary tumor transforming gene causes aneuploidy and p53-dependent and p53-independent apoptosis. J Biol Chem (2000) 1.24
Modulation of the transcriptional activity of thyroid hormone receptors by the tumor suppressor p53. Proc Natl Acad Sci U S A (1996) 1.15
Mechanisms that mediate negative regulation of the thyroid-stimulating hormone alpha gene by the thyroid hormone receptor. J Biol Chem (1999) 1.13
Is there a negative TRE in the luciferase reporter cDNA? Thyroid (1996) 1.12
SUG1, a putative transcriptional mediator and subunit of the PA700 proteasome regulatory complex, is a DNA helicase. J Biol Chem (1997) 1.12
Regulation of the 26S proteasome by adenovirus E1A. EMBO J (2000) 1.09
Stoichiometric phosphorylation of human p53 at Ser315 stimulates p53-dependent transcription. J Biol Chem (2000) 1.05
Multiple sequences encoding potential thyroid hormone receptors isolated from mouse skeletal muscle cDNA libraries. Nucleic Acids Res (1988) 1.01
Adenovirus early region 1A protein binds to mammalian SUG1-a regulatory component of the proteasome. Oncogene (1999) 0.93
Thyroid hormone promotes serine phosphorylation of p53 by mitogen-activated protein kinase. Biochemistry (2001) 0.91
Thyroid hormone receptor coactivators and corepressors. Thyroid (1998) 0.88
Differential regulation of the human thyrotropin alpha-subunit promoter by thyroid hormone receptors alpha1 and beta1. Thyroid (1998) 0.86
Tumor suppressor p53 is a negative regulator in thyroid hormone receptor signaling pathways. J Biol Chem (1997) 0.85
The adenovirus E1A protein is a potent coactivator for thyroid hormone receptors. Mol Endocrinol (1999) 0.85
Mechanisms of transcriptional regulation of cellular genes by SV40 large T- and small T-antigens. Virus Genes (1997) 0.84
A potential role for cell cycle control proteins in regulation of the cyclic adenosine 5'-monophosphate-responsive glycoprotein hormone alpha subunit gene. Cell Growth Differ (1996) 0.80
Thyroid receptor alpha1 and alpha2 mutations in nonfunctioning pituitary tumors. J Clin Endocrinol Metab (1999) 0.80
Estradiol modulates thyroid hormone regulation of the human glycoprotein hormone alpha subunit gene. J Biol Chem (1993) 0.77
Thyroid hormone and estrogen receptor expression in normal pituitary and nonfunctioning tumors of the anterior pituitary. J Clin Endocrinol Metab (1997) 0.77
Analysis of the p53 gene in human choriocarcinoma cell lines. Br J Cancer (1995) 0.77
Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature (2003) 13.00
Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet (2007) 12.62
Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls. Nature (2010) 12.27
Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA (2004) 8.12
Subclinical hypothyroidism and the risk of coronary heart disease and mortality. JAMA (2010) 5.20
Iodine status of UK schoolgirls: a cross-sectional survey. Lancet (2011) 4.96
Replication of an association between the lymphoid tyrosine phosphatase locus (LYP/PTPN22) with type 1 diabetes, and evidence for its role as a general autoimmunity locus. Diabetes (2004) 4.81
Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. N Engl J Med (2012) 4.59
Prevalence and relative risk of other autoimmune diseases in subjects with autoimmune thyroid disease. Am J Med (2010) 3.24
Association of the interleukin-2 receptor alpha (IL-2Ralpha)/CD25 gene region with Graves' disease using a multilocus test and tag SNPs. Clin Endocrinol (Oxf) (2007) 3.17
Iodine supplementation for pregnancy and lactation-United States and Canada: recommendations of the American Thyroid Association. Thyroid (2006) 2.56
Subclinical hyperthyroidism and the risk of coronary heart disease and mortality. Arch Intern Med (2012) 2.24
Parameters for reliable results in genetic association studies in common disease. Nat Genet (2002) 2.00
Tumour angiogenesis is reduced in the Tc1 mouse model of Down's syndrome. Nature (2010) 1.70
A single nucleotide polymorphism in the CD40 gene on chromosome 20q (GD-2) provides no evidence for susceptibility to Graves' disease in UK Caucasians. Clin Endocrinol (Oxf) (2004) 1.64
Cardiovascular manifestations of hyperthyroidism before and after antithyroid therapy: a matched case-control study. J Am Coll Cardiol (2006) 1.59
Seven newly identified loci for autoimmune thyroid disease. Hum Mol Genet (2012) 1.57
Regulation of DNA-end resection by hnRNPU-like proteins promotes DNA double-strand break signaling and repair. Mol Cell (2012) 1.50
Mapping between Visual Analogue Scale and Standard Gamble data; results from the UK Health Utilities Index 2 valuation survey. Health Econ (2006) 1.49
Association of the TSHR gene with Graves' disease: the first disease specific locus. Eur J Hum Genet (2005) 1.49
Regression mapping of association between the human leukocyte antigen region and Graves disease. Am J Hum Genet (2004) 1.47
Childhood weight gain and thyroid autoimmunity at age 60-64 years: the 1946 British birth cohort study. J Clin Endocrinol Metab (2013) 1.45
A comparative quality assessment of evidence-based clinical guidelines in endocrinology. Clin Endocrinol (Oxf) (2013) 1.42
Cardiovascular abnormalities in hyperthyroidism. Am J Med (2005) 1.38
Funding the unfundable: mechanisms for managing uncertainty in decisions on the introduction of new and innovative technologies into healthcare systems. Pharmacoeconomics (2010) 1.37
The APC/C and CBP/p300 cooperate to regulate transcription and cell-cycle progression. Nature (2005) 1.37
131I activity for remnant ablation in patients with differentiated thyroid cancer: A systematic review. J Clin Endocrinol Metab (2006) 1.35
A novel and major association of HLA-C in Graves' disease that eclipses the classical HLA-DRB1 effect. Hum Mol Genet (2007) 1.35
Prevalence of subclinical thyroid dysfunction and its relation to socioeconomic deprivation in the elderly: a community-based cross-sectional survey. J Clin Endocrinol Metab (2006) 1.30
Association of the thyroid stimulating hormone receptor gene (TSHR) with Graves' disease. Hum Mol Genet (2009) 1.26
Adenovirus 12 E4orf6 inhibits ATR activation by promoting TOPBP1 degradation. Proc Natl Acad Sci U S A (2010) 1.17
Pituitary tumour transforming gene (PTTG) induces genetic instability in thyroid cells. Oncogene (2005) 1.14
Adenovirus E1B 55-kilodalton protein: multiple roles in viral infection and cell transformation. J Virol (2009) 1.14
A role for E1B-AP5 in ATR signaling pathways during adenovirus infection. J Virol (2008) 1.11
Recruitment of CBP/p300, TATA-binding protein, and S8 to distinct regions at the N terminus of adenovirus E1A. J Virol (2005) 1.08
Mediator of DNA damage checkpoint 1 (MDC1) regulates mitotic progression. J Biol Chem (2009) 1.08
A novel mechanism of sodium iodide symporter repression in differentiated thyroid cancer. J Cell Sci (2009) 1.06
Association of PTPN22 haplotypes with Graves' disease. J Clin Endocrinol Metab (2006) 1.05
Epigenetic control of a VDR-governed feed-forward loop that regulates p21(waf1/cip1) expression and function in non-malignant prostate cells. Nucleic Acids Res (2010) 1.03
Pituitary tumor transforming gene binding factor: a new gene in breast cancer. Cancer Res (2010) 1.02
Transcriptional control by adenovirus E1A conserved region 3 via p300/CBP. Nucleic Acids Res (2009) 1.01
Roles for APIS and the 20S proteasome in adenovirus E1A-dependent transcription. EMBO J (2006) 1.01
The ND10 component promyelocytic leukemia protein relocates to human papillomavirus type 1 E4 intranuclear inclusion bodies in cultured keratinocytes and in warts. J Virol (2003) 1.01
Pituitary tumor-transforming gene and its binding factor in endocrine cancer. Expert Rev Mol Med (2010) 1.01
Differences in the recurrence and mortality outcomes rates of incidental and nonincidental papillary thyroid microcarcinoma: a systematic review and meta-analysis of 21 329 person-years of follow-up. J Clin Endocrinol Metab (2014) 1.00
Polymorphism of the CTLA-4 gene is associated with autoimmune hypothyroidism in the United Kingdom. Thyroid (2002) 0.98
Serotype-specific inactivation of the cellular DNA damage response during adenovirus infection. J Virol (2010) 0.98
Pituitary tumor transforming gene binding factor: a novel transforming gene in thyroid tumorigenesis. J Clin Endocrinol Metab (2005) 0.98
Identification of a second CtBP binding site in adenovirus type 5 E1A conserved region 3. J Virol (2008) 0.96
Elevated NCOR1 disrupts PPARalpha/gamma signaling in prostate cancer and forms a targetable epigenetic lesion. Carcinogenesis (2010) 0.95
Hyperthyroidism and cardiovascular morbidity and mortality. Thyroid (2002) 0.95
Early expression of thyroid hormone deiodinases and receptors in human fetal cerebral cortex. Brain Res Dev Brain Res (2002) 0.92
The relationship between serum TSH and free T4 in older people. J Clin Pathol (2012) 0.92
Principles of design of access with evidence development approaches: a consensus statement from the Banff Summit. Pharmacoeconomics (2010) 0.91
Recruitment of NCOR1 to VDR target genes is enhanced in prostate cancer cells and associates with altered DNA methylation patterns. Carcinogenesis (2012) 0.91
Expression and function of the novel proto-oncogene PBF in thyroid cancer: a new target for augmenting radioiodine uptake. J Endocrinol (2011) 0.91
Thyroid stimulating hormone receptor (TSHR) intron 1 variants are major risk factors for Graves' disease in three European Caucasian cohorts. PLoS One (2010) 0.90
Proto-oncogene PBF/PTTG1IP regulates thyroid cell growth and represses radioiodide treatment. Cancer Res (2011) 0.90
Adenovirus E1A interacts directly with, and regulates the level of expression of, the immunoproteasome component MECL1. Virology (2011) 0.90
The interaction of the hnRNP family member E1B-AP5 with p53. FEBS Lett (2005) 0.89
Identification of a second independent binding site for the pCAF acetyltransferase in adenovirus E1A. Virology (2009) 0.89
Cooperation between different forms of the human papillomavirus type 1 E4 protein to block cell cycle progression and cellular DNA synthesis. J Virol (2004) 0.89
Adenovirus E4orf3 targets transcriptional intermediary factor 1γ for proteasome-dependent degradation during infection. J Virol (2011) 0.88
Patient information in Graves' disease and thyroid-associated ophthalmopathy: readability assessment of online resources. Thyroid (2013) 0.88
Role for Wee1 in inhibition of G2-to-M transition through the cooperation of distinct human papillomavirus type 1 E4 proteins. J Virol (2006) 0.87
Detection and surgical treatment of cervical lymph nodes in differentiated thyroid cancer. Thyroid (2006) 0.87
The targeting of the proteasomal regulatory subunit S2 by adenovirus E1A causes inhibition of proteasomal activity and increased p53 expression. J Biol Chem (2004) 0.87
Confirmation of association of chromosome 5q31-33 with United Kingdom Caucasian Graves' disease. Thyroid (2010) 0.86
Skewed X chromosome inactivation and female preponderance in autoimmune thyroid disease: an association study and meta-analysis. J Clin Endocrinol Metab (2013) 0.86
Placental transport of thyroid hormone. Best Pract Res Clin Endocrinol Metab (2007) 0.85
Successful treatment of amiodarone-induced thyrotoxicosis. Circulation (2002) 0.84
The PTTG1-binding factor (PBF/PTTG1IP) regulates p53 activity in thyroid cells. Endocrinology (2014) 0.84
Association of Fc receptor-like 5 (FCRL5) with Graves' disease is secondary to the effect of FCRL3. Clin Endocrinol (Oxf) (2010) 0.83